Awakening guardian angels: drugging the p53 pathway

Cited by (914)

Items 201–300 of 914

1. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma
   Danielle M. Patterson, Dongbing Gao, Denae N. Trahan, Brett A. Johnson, Andrew D. Ludwig, Eveline Barbieri, Zaowen Chen, Jose Luis Diaz-Miron, Lyubomir T. Vassilev, Jason Matthew Shohet et al. · 2011 · Angiogenesis
2. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor
   Jerson Lima Silva, Luciana Pereira Rangel, Danielly C. Ferraz da Costa, Yraima Cordeiro, C. V. de Moura Gallo · 2013 · Bioscience Reports
3. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity
   Julien Viotti, Eric Duplan, Céline Caillava, J Condat, Thomas Goiran, Cécile Giordano, Yannick Marie, Ahmed Idbaïh, J-Y Delattre, Jérôme Honnorat et al. · 2013 · Oncogene
4. Regulation of the p53 pathway by ubiquitin and related proteins
   Andreas Hock, Karen H. Vousden · 2010 · The International Journal of Biochemistry & Cell Biology
5. A biomimetic polyketide-inspired approach to small-molecule ligand discovery
   Claudio Aquino, Mohosin Sarkar, Michael J. Chalmers, Kimberly Mendes, Thomas J. Kodadek, Glenn C. Micalizio · 2011 · Nature Chemistry
6. Multicomponent Solvent-Free Synthesis Of Benzimidazolyl Imidazo[1,2-a]-pyridine Under Microwave Irradiation
   Barnali Maiti, Kaushik Chanda, Manikandan Selvaraju, Chih‐Chung Tseng, Chung‐Ming Sun · 2013 · ACS Combinatorial Science
7. Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents
   Carlos J. A. Ribeiro, Joana D. Amaral, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2013 · Bioorganic & Medicinal Chemistry
8. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
   Sullivan, Kelly D, Padilla-Just, Nuria, Henry, Ryan E, Porter, Christopher C, Kim, Jihye, Tentler, John J, Eckhardt, S Gail, Tan, Aik Choon, DeGregori, James, Espinosa, Joaquín M · 2012 · Nature Chemical Biology
9. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
   Zhao, Carolyn Y., Grinkevich, Vera, Nikulenkov, Fedor, Bao, Wenjie, Selivanova, Galina · 2010 · Cell Cycle
10. Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?
    Oktay Tacar, Crispin R. Dass · 2013 · Journal of Pharmacy and Pharmacology
11. Regulation of p53 Stability and Apoptosis by a ROR Agonist
    Yongjun Wang, Laura A. Solt, Douglas J. Kojetin, Thomas P. Burris · 2012 · PLoS ONE
12. Drug discovery and mutant p53
    Magdalena M. Maslon, Ted R. Hupp · 2010 · Trends in Cell Biology
13. A Genetic Screen Identifies TCF3/E2A and TRIAP1 as Pathway-Specific Regulators of the Cellular Response to p53 Activation
    Zdeněk Andrysík, Jihye Kim, Aik Choon Tan, Joaquin Maximiliano Espinosa · 2013 · Cell Reports
14. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury
    Yashashree Joshi, Marília Grando Sória, Giorgia Quadrato, Gizem Inak, Luming Zhou, Arnau Hervera, Khizr I. Rathore, Mohamed Elnaggar, Magali Cucchiarini, Jean‐Christophe Marine et al. · 2015 · Brain
15. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
    YEE-LIN VOON, Pooi‐Fong Wong, Alan Soo Beng Khoo · 2017 · Mini-Reviews in Medicinal Chemistry
16. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
    Xia, M, Knezevic, D, Vassilev, L T · 2011 · Oncogene
17. H2O-mediated isatin spiro-epoxide ring opening with NaCN: Synthesis of novel 3-tetrazolylmethyl-3-hydroxy-oxindole hybrids and their anticancer evaluation
    Pankaj Sharma, Kishna Ram Senwar, Manish Kumar Jeengar, T. Srinivasa Reddy, V.G.M. Naidu, Ähmed Kamal, Nagula Shankaraiah · 2015 · European Journal of Medicinal Chemistry
18. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study
    Balu Kamaraj, Annemie Bogaerts · 2015 · PLoS ONE
19. Synthesis, single crystal and antitumor activities of benzimidazole–quinazoline hybrids
    Alka Sharma, Vijay Luxami, Kamaldeep Paul · 2013 · Bioorganic & Medicinal Chemistry Letters
20. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Xin Yu, Sumana Narayanan, Alexei Vázquez, Darren R. Carpizo · 2014 · APOPTOSIS
21. Facilitated Diffusion Mechanisms in DNA Base Excision Repair and Transcriptional Activation
    Alexandre Esadze, James T. Stivers · 2018 · Chemical Reviews
22. Mirror image proteins
    Le Zhao, Wuyuan Lu · 2014 · Current Opinion in Chemical Biology
23. Polo-like kinase-1 in DNA damage response
    Sun‐Yi Hyun, Hyo-In Hwan, Young‐Joo Jang · 2014 · BMB Reports
24. Development of covalent inhibitors: Principle, design, and application in cancer
    Zheng, Lang, Li, Yang, Wu, Defa, Xiao, Huan, Zheng, Shilong, Wang, Guan, Sun, Qiu · 2023 · MedComm – Oncology
25. Role of Tip60 in Human Melanoma Cell Migration, Metastasis, and Patient Survival
    Guangdi Chen, Yabin Cheng, Yun Tang, Magdalena Martinka, Gang Li · 2012 · Journal of Investigative Dermatology
26. Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
    Mohan R. Pradhan, Jia Wei Siau, Srinivasaraghavan Kannan, Minh N. Nguyen, Zohra Ouaray, Chee Keong Kwoh, David Philip Lane, Farid John Ghadessy, Chandra Shekhar Verma · 2019 · Nucleic Acids Research
27. TRIM69 inhibits cataractogenesis by negatively regulating p53
    Xianfang Rong, Jun Rao, Dan Li, Qinghe Jing, Yi Lü, Yinghong Ji · 2019 · Redox Biology
28. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
    Andrea Weilbacher, Matthias Gutekunst, Moshe Oren, Walter E. Aulitzky, Heiko van der Kuip · 2014 · Cell Death and Disease
29. A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB Topoisomerase
    Sourav Taru Saha, Chiranjit Acharya, Uttam Pal, Somenath Roy Chowdhury, Kahini Sarkar, Nakul C. Maiti, Parasuraman Jaisankar, Hemanta Kumar Majumder · 2016 · Antimicrobial Agents and Chemotherapy
30. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
    Chiao‐En Wu, Arman Esfandiari, Yi-Hsuan Ho, Nan Wang, Ahmed Khairallah Mahdi, Erhan Aptullahoğlu, Penny E. Lovat, John Lunec · 2017 · British Journal of Cancer
31. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
    Zhang, Zhuming, Ding, Qingjie, Liu, Jin-Jun, Zhang, Jing, Jiang, Nan, Chu, Xin-Jie, Bartkovitz, David, Luk, Kin-Chun, Janson, Cheryl, Tovar, Christian et al. · 2014 · Bioorganic & Medicinal Chemistry
32. p53 Is Positively Regulated by miR-542-3p
    Yemin Wang, Jen‐Wei Huang, María Castellà, David D. Huntsman, Toshiyasu Taniguchi · 2014 · Cancer Research
33. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation
    Xishan Chen, Lingyu Tai, Jie Gao, Jianchang Qian, Mingfei Zhang, Beibei Li, Cao Xie, Linwei Lu, Wuyuan Lu, Weiyue Lu · 2015 · Journal of Controlled Release
34. Investigating peptide sequence variations for ‘double-click’ stapled p53 peptides
    Yu Heng Lau, Peterson de Andrade, Niklas Sköld, Grahame J. McKenzie, Ashok R. Venkitaraman, Chandra Shekhar Verma, David Philip Lane, David R. Spring · 2014 · Organic & Biomolecular Chemistry
35. Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia
    Amaia Vilas‐Zornoza, Xabier Agirre, Vanesa Martín‐Palanco, José Ignacio Martín-Subero, Edurne San José‐Eneriz, Leire Gárate, Sara Álvarez, Estíbaliz Miranda, Paula Rodríguez‐Otero, J. Rifón et al. · 2011 · PLoS ONE
36. Direct and Propagated Effects of Small Molecules on Protein–Protein Interaction Networks
    Laura C. Cesa, Anna K. Mapp, Jason E. Gestwicki · 2015 · Frontiers in Bioengineering and Biotechnology
37. Selective killing of p53‐deficient cancer cells by SP600125
    Mohamed Jèmaà, Ilio Vitale, Oliver Kepp, Francesco Berardinelli, Lorenzo Galluzzi, Laura Senovilla, Guillermo Mariño, Shoaib Ahmad Malik, Santiago Rello‐Varona, Delphine Lissa et al. · 2012 · EMBO Molecular Medicine
38. p38MAPK and ERK1/2 dictate cell death/survival response to different pro-oxidant stimuli via p53 and Nrf2 in neuroblastoma cells SH-SY5Y
    Giuseppe Filomeni, Sara Piccirillo, Giuseppe Rotilio, Maria Rosa Ciriolo · 2012 · Biochemical Pharmacology
39. Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency
    Sergio Ménendez, Suzanne Camus, Aida Herreria, Ida Paramonov, Laura Batlle‐Morera, Manuel Collado, Vladimír Pekařík, Iago Maceda, Michael J. Edel, Antonella Consiglio et al. · 2011 · Aging Cell
40. Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance
    Jad I. Belle, Jessica C. Petrov, David Langlais, François Robert, Regina Cencic, Shiyang Shen, Jerry Pelletier, Philippe Gros, Anastasia Nijnik · 2016 · Cell Death and Differentiation
41. p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
    Mohammad Krayem, Fabrice Journé, Murielle Wiedig, Renato Morandini, Ahmad Najem, François Salès, Léon C.L.T. van Kempen, Catherine Sibille, Ahmad Hussein Awada, Jean‐Christophe Marine et al. · 2016 · European Journal of Cancer
42. Role of TP53 Mutations in Vulvar Carcinomas
    Matthias Choschzick, Widianto Hantaredja, Pierre Tennstedt, Frederike Gieseking, Linn Lena Woelber, Ronald Simon · 2011 · International Journal of Gynecological Pathology
43. Prion-like p53 Amyloids in Cancer
    Ambuja Navalkar, Saikat Ghosh, Satyaprakash Pandey, Ajoy Paul, Debalina Datta, Samir Kumar Maji · 2019 · Biochemistry
44. New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives
    Marı́a Font, Álvaro González, Juan Antonio Palop, Carmen Sanmartín · 2011 · European Journal of Medicinal Chemistry
45. p53 immunohistochemistry in bladder cancer—a new approach to an old question
    Peter Juergen Goebell, Susan G. Groshen, Bernd J. Schmitz‐Dräger · 2010 · Urologic Oncology Seminars and Original Investigations
46. Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction
    Michał Biśta, Siglinde Wolf, Kareem Khoury, Kaja Kowalska, Yijun Huang, Ewa Wrona, Marcelino Arciniega, Grzegorz M. Popowicz, Tad A. Holak, Alexander S. S. Dömling · 2013 · Structure
47. Large Extent of Disorder in Adenomatous Polyposis Coli Offers a Strategy to Guard Wnt Signalling against Point Mutations
    David‐Paul Minde, Martina Radli, Federico Forneris, Madelon M. Maurice, Stefan Rüdiger · 2013 · PLoS ONE
48. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma
    Liping Dai, Pengfei Ren, Mei Liu, Haruhiko Imai, Eng M. Tan, Jian Ying Zhang · 2014 · Clinical Immunology
49. Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
    Jiang‐Jiang Qin, Subhasree Ashok Nag, Sukesh Voruganti, W. Wang, Ruifeng Zhang · 2012 · Current Medicinal Chemistry
50. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival
    Lisa K. Mullany, Kwong‐Kwok Wong, David C. Marciano, Panagiotis Katsonis, Erin R. King, Yi Athena Ren, Olivier Lichtarge, JoAnne S. Richards · 2015 · Neoplasia
51. Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors
    Emil Bulatov, Regina Sayarova, Rimma N. Mingaleeva, Мифтахова Регина Рифкатовна, Marina O. Gomzikova, Yuri Ignatyev, Alexey Petukhov, Pavel B. Davidovich, Albert Anatolyevich Rizvanov, Nickolai A. Barlev · 2018 · Cell Death Discovery
52. WIP1 phosphatase as pharmacological target in cancer therapy
    Soňa Pecháčková, Kamila Burdová, Libor Macůrek · 2017 · Journal of Molecular Medicine
53. Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway
    Hao Ruan, Yu Chen, Xiaogang Niu, Weilin Zhang, Hanzhong Liu, Limin Chen, Ruoyao Xiong, Qi Sun, Changwen Jin, Ying Liu et al. · 2020 · Chemical Science
54. Structural and sequential context of p53: A review of experimental and theoretical evidence
    Taniya Saha, Rajiv K. Kar, Gaurisankar Sa · 2014 · Progress in Biophysics and Molecular Biology
55. The role of the endosomal sorting complexes required for transport (ESCRT) in tumorigenesis
    Claudia Mattissek, David Teis · 2014 · Molecular Membrane Biology
56. Stabilization of protein–protein interactions by small molecules
    Fabrizio Giordanetto, Anja Schäfer, Christian Ottmann · 2014 · Drug Discovery Today
57. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression
    Amrendra K. Ajay, Ankur Kumar Upadhyay, Sandeep Singh, Maleppillil Vavachan Vijayakumar, Ratna Kumari V, Vimal Pandey, Ramanamurthy Boppana, Manoj Kumar Bhat · 2010 · Molecular Cancer
58. Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer
    Hirohito Yamaguchi, Jennifer L. Hsu, Mien‐Chie Hung · 2012 · Frontiers in Oncology
59. Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
    Abygail G. Chapdelaine, Gongqin Sun · 2023 · Biomolecules
60. Structure-Based Design of Small-Molecule Protein–Protein Interaction Modulators: The Story so Far
    Federico Falchi, Fabiana Caporuscio, Maurizio Recanatini · 2014 · Future Medicinal Chemistry
61. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function
    Ofer Margalit, Amos J. Simon, Eduard Yakubov, Rosa Puca, Ady Yosepovich, Camila Avivi, Jasmine Jacob‐Hirsch, Ilana Gelernter, Alon Harmelin, Iris Barshack et al. · 2011 · International Journal of Cancer
62. Apoptosis assays for quantifying the bioactivity of anticancer drug products
    Joslyn K. Brunelle, Baolin Zhang · 2010 · Drug Resistance Updates
63. De Novo Nano‐Erythrocyte Structurally Braced by Biomimetic Au(I)‐peptide Skeleton for MDM2/MDMX Predation toward Augmented Pulmonary Adenocarcinoma Immunotherapy
    Xiaoqiang Zheng, Jin Yan, Weiming You, Fanni Li, Jiajie Diao, Wangxiao He, Yu Yao · 2021 · Small
64. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity
    Yuqin Di, Xiaoqian Jing, Kunhua Hu, Xiangqiong Wen, Lvlan Ye, Xiang Zhang, Jiale Qin, Jinning Ye, Run Lin, Ziyang Wang et al. · 2022 · Drug Resistance Updates
65. Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy
    Nikolina Vlatković, Mark T. Boyd, Carlos P. Rubbi · 2013 · Cellular and Molecular Life Sciences
66. Small Molecules That Target Protein Misfolding
    Lori Krim Gavrin, R. Aldrin Denny, Eddine Saiah · 2012 · Journal of Medicinal Chemistry
67. The nucleoside analog clitocine is a potent and efficacious readthrough agent
    Westley J. Friesen, Christopher R. Trotta, Yuki Tomizawa, Jin Zhuo, Briana Johnson, Jairo Sierra, Bijoyita Roy, Marla L. Weetall, Jean Hedrick, Josephine Sheedy et al. · 2017 · RNA
68. Targeting the nucleolus for cancer-specific activation of p53
    Denis Drygin, Sean O’Brien, Ross D. Hannan, Grant A. McArthur, Daniel D. Von Hoff · 2013 · Drug Discovery Today
69. Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells
    Mara Cirone, Alessia Garufi, Livia Di Renzo, Marisa Granato, Alberto Faggioni, Gabriella D’Orazi · 2013 · OncoImmunology
70. HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation
    Lavinia Nardinocchi, Rosa Puca, Gabriella D’Orazi · 2011 · Aging
71. Cell death-based treatment of neuroblastoma
    Kadri Valter, Boris Zhivotovsky, Vladimir G. Gogvadze · 2018 · Cell Death and Disease
72. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China
    Yu Xia, Xiuqin Li, Wei Sun · 2020 · Current Gene Therapy
73. Ubiquitylation of p53 by the APC/C inhibitor Trim39
    Liguo Zhang, Nai-Jia Huang, Chen Chen, Wanli Tang, Sally A. Kornbluth · 2012 · Proceedings of the National Academy of Sciences
74. Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway
    Zhuang, Chunlin, Miao, Zhenyuan, Wu, Yuelin, Guo, Zizhao, Li, Jin, Yao, Jianzhong, Xing, Chengguo, Sheng, Chunquan, Zhang, Wannian · 2014 · Journal of Medicinal Chemistry
75. Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C
    Joseph R. Stephenson Clarke, Leon R. Douglas, Patrick J. Duriez, Dimitrios-Ilias Balourdas, Andreas C. Joerger, Raniya Khadiullina, Emil Bulatov, Matthias G. J. Baud · 2022 · ACS Pharmacology & Translational Science
76. Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer
    Hilal Koçdor, Halil Ateş, Süleyman Aydın, Rüksan Çehreli, Firat Soyarat, Pinar Kemanli, Duygu Harmancı, Hakan Cengiz, Mehmet Ali Koçdor · 2015 · Drug Design Development and Therapy
77. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway
    Huanhuan Chen, Yuechun Huang, Junbin Huang, L. Lin, Gang Wei · 2016 · Oncology Reports
78. High-throughput screening for modulators of protein–protein interactions: use of photonic crystal biosensors and complementary technologies
    James T. Heeres, Paul J. Hergenrother · 2010 · Chemical Society Reviews
79. Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined
    Changyou Zhan, Kristen M. Varney, Weirong Yuan, Le Zhao, Wuyuan Lu · 2012 · Journal of the American Chemical Society
80. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
    Vivek Subbiah, Michael J. Wagner, Mary F. McGuire, Nawid Sarwari, Eswaran Devarajan, Valerae Olive Lewis, Shanon Westin, Shumei Kato, Robert Eldon Brown, Pete M. Anderson · 2015 · Oncotarget
81. Systems biology analysis reveals role of MDM2 in diabetic nephropathy
    Rintaro Saito, Anaïs Rocañín Arjó, Young-Hyun You, Manjula Darshi, Benjamin Van Espen, Satoshi Miyamoto, Jessica Pham, Minya Pu, Simone Romoli, Loki Natarajan et al. · 2016 · JCI Insight
82. TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
    Binsah George, Hagop M. Kantarjian, Natalia Baran, Joseph D. Krocker, Adan A. Rios · 2021 · International Journal of Molecular Sciences
83. Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
    Azmi, Asfar S., Banerjee, Sanjeev, Ali, Shadan, Wang, Zhiwei, Bao, Bin, Beck, Frances W.J., Maitah, Main, Choi, Minsig, Shields, Tony F., Philip, Philip A. et al. · 2011 · Oncotarget
84. Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells
    Nina‐Naomi Kreis, Mourad Sanhaji, Andrea Krämer, Katharina Sommer, Franz Rödel, Klaus Strebhardt, Juping Yuan · 2010 · Oncogene
85. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
    Asfar Sohail Azmi, P. A. Philip, F W Beck, Zhiwei Wang, Sohom Banerjee, Shaomeng Wang, Dajun Yang, Fazlul H. Sarkar, Ramzi M. Mohammad · 2010 · Oncogene
86. Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
    D Pan, L-Z Pan, Richard Hill, Paola Marcato, Maya Shmulevitz, Lyubomir T. Vassilev, P. W. K. Lee · 2011 · British Journal of Cancer
87. Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light
    Mickel J. Hansen, Femke M. Feringa, Piermichele Kobauri, Wiktor Szymański, René H. Medema, Ben L. Feringa · 2018 · Journal of the American Chemical Society
88. Recent Advances in Cancer Therapeutics
    Nicola E. A. Chessum, Keith Jones, Elisa Pasqua, Michael Tucker · 2015 · Progress in medicinal chemistry
89. Targeting transcription factors in acute myeloid leukemia
    Hisashi Takei, Susumu S. Kobayashi · 2018 · International Journal of Hematology
90. Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53
    Jialiang Shao, Jiongjiong Lu, Wencheng Zhu, Hua Tao Yu, Xiaoqian Jing, Yilin Wang, Xiang Wang, Xiongjun Wang · 2019 · Cell Death and Differentiation
91. Avian Reovirus Protein p17 Functions as a Nucleoporin Tpr Suppressor Leading to Activation of p53, p21 and PTEN and Inactivation of PI3K/AKT/mTOR and ERK Signaling Pathways
    Wei‐Ru Huang, Hung‐Chuan Chiu, Tsai‐Ling Liao, Kuo‐Pin Chuang, Wing-Ling Shih, Hung‐Jen Liu · 2015 · PLoS ONE
92. Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists
    Arun Chandramohan, Hubert B. Josien, Tsz Ying Yuen, Ruchia Duggal, Diana Spiegelberg, Lin Yuan Yan, Yu-Chi Angela Juang, Lan Ge, Pietro G. A. Aronica, Hung Yi Kristal Kaan et al. · 2024 · Nature Communications
93. Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
    Ingeborg M.M. van Leeuwen, Maureen Higgins, Johanna Campbell, Anna R. McCarthy, Marijke C.C. Sachweh, Ana Marín Navarro, Sonia Laín · 2013 · Molecular Cancer Therapeutics
94. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
    Arman Esfandiari, Thomas A. Hawthorne, Sirintra Nakjang, John Lunec · 2016 · Molecular Cancer Therapeutics
95. Correction: Avian Reovirus Protein p17 Functions as a Nucleoporin Tpr Suppressor Leading to Activation of p53, p21 and PTEN and Inactivation of PI3K/AKT/mTOR and ERK Signaling Pathways
    Wei‐Ru Huang, Hung‐Chuan Chiu, Tsai‐Ling Liao, Kuo‐Pin Chuang, Wing-Ling Shih, Hung‐Jen Liu · 2015 · PLoS ONE
96. Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
    Ma, Buyong, Nussinov, Ruth · 2014 · Current Pharmaceutical Design
97. Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule
    Tae‐Wook Kang, Soon Won Choi, Se‐Ran Yang, Tae–Hoon Shin, Hyung‐Sik Kim, Kyung–Rok Yu, In‐Sun Hong, Seonggu Ro, Joong Myung Cho, Kyung‐Sun Kang · 2014 · Scientific Reports
98. Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids
    Mostafa Mohammed Ghorab, Mansour S. Alsaid, Mohammed Salem Al-Dosari, Marwa Galal El-Gazzar, Mohammad Khalid Parvez · 2016 · Molecules
99. Towards vast libraries of scaffold-diverse, conformationally constrained oligomers
    Thomas J. Kodadek, Patrick J. McEnaney · 2016 · Chemical Communications
100. The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53
     Esha Madan, Taylor M. Parker, Matthias R. Bauer, Alisha Dhiman, Christopher James Pelham, Masaki Nagane, M. Lakshmi Kuppusamy, Matti Holmes, Thomas R. Holmes, Kranti Shaik et al. · 2018 · Journal of Biological Chemistry